Juhász Margit, Yale Katerina L, Thatiparthi Akshitha, Babadjouni Arash, Mesinkovska Natasha Atanaskova
Drs. Juhász, Yale, and Mesinkovska are with the Department of Dermatology at the University of California Irvine in Irvine, California.
Ms. Thatiparthi is with Western University of Health Sciences and the College of Osteopathic Medicine of the Pacific in Pomona, California.
J Clin Aesthet Dermatol. 2023 Feb;16(2):14-18.
Microfocused ultrasound with visualization (MFU-V) and calcium hydroxylapatite (CaHA) filler are modalities for improving skin laxity. Their use in combination on body sites other than the face is expanding.
To investigate the effectiveness and safety of combination MFU-V and dilute CaHA (dCaHA) for lower anterior thigh and knee laxity over 12 and 24 weeks.
Twenty women (40-71 years) with moderate to severe laxity of the anterior thigh and knee were enrolled in this split-body trial. Subjects received dual-depth (3.0mm, 1.5mm) or triple-depth MFU-V (4.5mm, 3.0mm, 1.5mm) to the inferior anterior thigh (127-381 lines) along with dCaHA (1:1 normal saline) injection (0.5-3mL). Clinical effectiveness was monitored using photography, qualitative clinician and subject assessments, and quantitative analysis of skin topography by three-dimensional imaging and dermal thickness by optical coherence tomography.
At 12 and 24 weeks, the treated thigh and knee experienced significant improvement in qualitative clinician scales (<0.01), with subjective improvement on photography and subject-reported assessments; no significant changes were noted by quantitative measures. Adverse events were reported in 68 percent of patients, including mild bruising (n=12) and swelling (n=10).
Combining MFU-V and dCaHA is safe and results in clinical improvement of anterior thigh and knee laxity.
可视化微聚焦超声（MFU-V）和羟基磷灰石钙（CaHA）填充物是改善皮肤松弛的方法。它们在面部以外身体部位的联合应用正在不断扩展。
研究MFU-V与稀释CaHA（dCaHA）联合使用对大腿前下部和膝盖松弛情况在12周和24周内的有效性和安全性。
20名年龄在40 - 71岁之间、大腿前侧和膝盖中度至重度松弛的女性参与了这项分体试验。受试者接受对大腿前下部（127 - 381线）进行双深度（3.0毫米、1.5毫米）或三深度MFU-V（4.5毫米、3.0毫米、1.5毫米）治疗，并注射dCaHA（1:1生理盐水）（0.5 - 3毫升）。通过摄影、临床医生和受试者的定性评估以及三维成像对皮肤地形进行定量分析和光学相干断层扫描对真皮厚度进行监测来评估临床效果。
在12周和24周时，治疗后的大腿和膝盖在临床医生定性评分上有显著改善（<0.01），摄影和受试者报告评估显示主观上有改善；定量测量未发现显著变化。68%的患者报告了不良事件，包括轻度瘀伤（n = 12）和肿胀（n = 10）。
MFU-V与dCaHA联合使用是安全的，并且能在临床上改善大腿前侧和膝盖的松弛情况。
